COVID-19 Impact on Global Pyrogen Testing Market – Global Forecast to 2025

Pune, India, 2021-May-25 — /EPR Network/ —

The global pyrogen testing market size is projected to reach USD 1,689 million by 2025 from USD 927 million in 2020, at a CAGR of 12.7%. Market growth is driven by the growing focus on personalized medicine, increasing R&D in the pharmaceutical and biotechnology industries, rising prevalence of chronic diseases, the growing awareness of food safety, and the rising incidence of infectious diseases and increasing frequency of pandemics.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255266155

COVID-19 Impact on Global Pyrogen Testing Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. With the World Health Organization (WHO) officially declared the outbreak of COVID-19, a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. According to the WHO, there are 70 vaccine candidates under development at present, and three candidates are already being tested in human trials. The pandemic’s economic and social burden has prompted government bodies globally to increase support for vaccine development, which has led to an increase in the adoption of pyrogen testing products for COVID-19 research. As vaccine manufacturing is expected to increase due to COVID-19, bacterial endotoxin testing will be an important quality assurance measure to ensure patient safety.

The assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market, by product & service segment, in 2019

Based on product & service, the pyrogen testing market is segmented into assays, kits, and reagents; instruments; and services. The assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market in 2019. The frequent requirement of assays, kits, and reagents in large numbers compared to instruments and the rising preference for kit-based testing are the major factors driving this segments growth.

LAL tests segment to register the highest growth rate during the forecast period

The pyrogen testing market is segmented into LAL tests, in vitro tests, and rabbit tests based on test type. In 2019, the LAL tests segment accounted for the highest growth rate. This can be attributed to the rising need for innovative laboratory testing procedures and the increasing support for vaccine development.

The pharmaceutical & biotechnology companies segment accounted for the largest share of the pyrogen testing market, by end user segment, in 2019

Based on end-users, the pyrogen testing market is segmented into pharmaceutical & biotechnology companies, medical device companies, and other end users. In 2019, pharmaceutical & biotechnology companies accounted for the largest share of the pyrogen testing market. High inclination towards outsourcing preclinical, clinical, and laboratory testing services, a large number of ongoing drug discovery activities, and the increasing number of R&D facilities globally are the major factors driving this segments growth.

North America is the largest regional market for pyrogen testing market

The pyrogen testing market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the pyrogen testing market. The large share of this region can be attributed to the rising prevalence of diseases, a growing number of drug approvals, increasing pharmaceutical drug pipelines, and growing consumer awareness about product safety.

The major players operating in this market are  Charles River Laboratories, Inc. (US), Lonza (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), Associates of Cape Cod, Inc. (US), GenScript Biotech Corporation (China), bioMérieux SA (France), FUJIFILM Wako Pure Chemical Corporation (Japan), Eurofins Scientific (Luxembourg), WuXi AppTec (China), Hycult Biotech (Netherlands), Ellab A/S (Denmark), Microcoat Biotechnologie GmbH (Germany), InvivoGen (US), Nelson Laboratories, LLC (US), Almac Group (UK), Pacific Biolabs (US), STERIS plc (US), Accugen Laboratories, Inc. (US), TOXIKON (US), Minerva Analytix GmbH (Germany), Indoor Biotechnologies, Inc. (US), Creative Bioarray (US), Lucideon Limited (UK), and North American Science Associates, Inc. (US).